Compound mutations in CML—imaginary bogeyman or real arch-nemesis?

David T. Yeung

doi:10.1016/j.leukres.2019.01.011

Compound mutations in CML—imaginary bogeyman or real arch-nemesis?

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	102-104
Number of pages	3
Journal	Leukemia Research
Volume	81
DOIs	https://doi.org/10.1016/j.leukres.2019.01.011
Publication status	Published or Issued - Jun 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2019.01.011

Cite this

@article{2a29cebc46e946269ca8bfb0decce394,

title = "Compound mutations in CML—imaginary bogeyman or real arch-nemesis?",

author = "Yeung, {David T.}",

note = "Funding Information: The author has received honoraria from Novartis, BMS, Pfizer, Ariad and Amgen, and research funding from BMS and Novartis. The author is an NHMRC Early Career Fellow. Funding Information: The author has received honoraria from Novartis, BMS, Pfizer, Ariad and Amgen, and research funding from BMS and Novartis . The author is an NHMRC Early Career Fellow.",

year = "2019",

month = jun,

doi = "10.1016/j.leukres.2019.01.011",

language = "English",

volume = "81",

pages = "102--104",

journal = "Leukemia Research",